Patent details
EP4076398 Title: LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-PEF)
Basic Information
- Publication number:
- EP4076398
- PCT Application Number:
- US2020065166
- Type:
- European Patent Granted for LU
- Legal Status:
- Unitary Effect Registered
- Application number:
- EP209008481
- PCT Publication Number:
- WO2021126884
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-PEF)
- French Title of Invention:
- LEVOSIMENDAN POUR TRAITER L'HYPERTENSION PULMONAIRE ACCOMPAGNÉE D'UNE INSUFFISANCE CARDIAQUE AU MOYEN D'UNE FRACTION D'ÉJECTION PRÉSERVÉE (PH-HF-PEF)
- German Title of Invention:
- LEVOSIMENDAN ZUM BEHANDELN DER PULMONALEN HYPERTENSION BEI HERZINSUFFIZIENZ MIT ERHALTENER AUSWURFFRAKTION (PH-HF-PEF)
- SPC Number:
Unitary Effect
- Unitary Effect Requested:
- Yes
- Unitary Effect Request Filing Date:
- 12/03/2026
- Link to UPP Register:
- European Patent Register
- Unitary Effect Request Withdrawal Date:
- Unitary Effect Status:
- Unitary Effect Registered
- Unitary Effect Acceptance Decision Date:
- 19/03/2026
- Unitary Effect Rejection Decision Date:
- Unitary Effect Date:
- 18/02/2026
- Unitary Effect Registration Date:
- 19/03/2026
- Unitary Effect Re-establishment of rights Filing Date:
- Unitary Effect Re-establishment of rights EPO Decision :
- Unitary Effect Re-establishment of rights EPO Decision Date:
- Explanatory Text UE:
- Safety Net Request Date:
- Safety Net Decision Date:
- Safety Net Decision Outcome:
- SPC Number:
Dates
- Filing date:
- 15/12/2020
- Grant date:
- 18/02/2026
- EP Publication Date:
- 26/10/2022
- PCT Publication Date:
- 24/06/2021
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 18/02/2026
- EP B1 Publication Date:
- 18/02/2026
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- Expiration date:
- 15/12/2040
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 11/02/2026
- Name:
- Tenax Therapeutics, Inc.
- Address:
- One Copley Parkway, Suite 490, Morrisville, NC 27560, United States (US)
Inventor
1
- Name:
- RICH, Stuart
- Address:
- United States (US)
2
- Name:
- HAY, Douglas
- Address:
- United States (US)
3
- Name:
- RANDALL, Douglas
- Address:
- United States (US)
Priority
1
- Priority Number:
- 201962948735 P
- Priority Date:
- 16/12/2019
- Priority Country:
- United States (US)
2
- Priority Number:
- 202062967920 P
- Priority Date:
- 30/01/2020
- Priority Country:
- United States (US)
3
- Priority Number:
- 202062988720 P
- Priority Date:
- 12/03/2020
- Priority Country:
- United States (US)
4
- Priority Number:
- 202063033773 P
- Priority Date:
- 02/06/2020
- Priority Country:
- United States (US)
5
- Priority Number:
- 202063064671 P
- Priority Date:
- 12/08/2020
- Priority Country:
- United States (US)
Classification
- IPC classification:
- A61K 31/216; A61K 9/08; A61K 31/41; A61K 31/495; A61K 31/50; A61P 9/04; A61P 9/12; A61K 9/00;
Publication
European Patent Bulletin
1
- Issue number:
- 202608
- Publication date:
- 18/02/2026
- Description:
- Grant (B1)
2
- Issue number:
- 202613
- Publication date:
- 25/03/2026
- Description:
- Application number/publication number of the divisional application (Art. 76) changed
3
- Issue number:
- 202616
- Publication date:
- 15/04/2026
- Description:
- Unitary Effect Request Receipt
4
- Issue number:
- 202617
- Publication date:
- 22/04/2026
- Description:
- Unitary Effect Request Acceptance
Annual Fees
- Annual Fee Due Date:
- Annual Fee Number:
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|